Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta.
Cairoli R, Beghini A, Turrini M, Bertani G, Nadali G, Rodeghiero F, Castagnola C, Lazzaroni F, Nichelatti M, Ferrara F, Pizzolo G, Pogliani E, Rossi G, Martinelli G, Morra E. Cairoli R, et al. Among authors: nichelatti m. Am J Hematol. 2013 Jul;88(7):594-600. doi: 10.1002/ajh.23461. Epub 2013 Jun 5. Am J Hematol. 2013. PMID: 23619823 Free article.
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.
Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, Colapietro P, Nichelatti M, Pezzetti L, Lunghi M, Cuneo A, Viola A, Ferrara F, Lazzarino M, Rodeghiero F, Pizzolo G, Larizza L, Morra E. Cairoli R, et al. Among authors: nichelatti m. Blood. 2006 May 1;107(9):3463-8. doi: 10.1182/blood-2005-09-3640. Epub 2005 Dec 29. Blood. 2006. PMID: 16384925 Free article.
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E. Montillo M, et al. Among authors: nichelatti m. J Clin Oncol. 2006 May 20;24(15):2337-42. doi: 10.1200/JCO.2005.04.6037. Epub 2006 Apr 17. J Clin Oncol. 2006. PMID: 16618945 Clinical Trial.
High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E. Tedeschi A, et al. Among authors: nichelatti m. Cancer Chemother Pharmacol. 2007 May;59(6):771-9. doi: 10.1007/s00280-006-0332-4. Epub 2007 Jan 26. Cancer Chemother Pharmacol. 2007. PMID: 17256136 Clinical Trial.
Total serum tryptase: a predictive marker for KIT mutation in acute myeloid leukemia.
Cairoli R, Ripamonti CB, Beghini A, Granata S, Grillo G, Brioschi M, Nadali G, Viola A, Cattaneo C, Inropido L, Ravelli E, Bertani G, Pezzetti L, Nichelatti M, Marocchi A, Rossi G, Pizzolo G, Ferrara F, Nosari AM, Morra E. Cairoli R, et al. Among authors: nichelatti m. Leuk Res. 2009 Sep;33(9):1282-4. doi: 10.1016/j.leukres.2009.03.043. Epub 2009 Apr 29. Leuk Res. 2009. PMID: 19406474
103 results